Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Recordati Acquires Six OTC Products

4/24/2012 2:45 PM ET

European pharmaceutical group Recordati Tuesday announced the acquisition of the marketing authorizations, the trademarks and additional assets concerning six OTC pharmaceuticals for Germany from Cilag GmbH International and McNeil GmbH & Co. oHG.

The products acquired are JHP-Rödler, BetadormD, Rhinopront, Collomack Topical, Tirgon and Xitix. The 2012 sales for the six products are estimated at around EUR 6 million.

Giovanni Recordati, chairman and CEO of the Recordati Group, said, "The OTC pharmaceutical segment in Germany represents 52 percent share in units of the overall pharmaceutical market."

Recordati added that together with the existing OTC portfolio, the German subsidiary will now be able to better exploit the OTC market potential by building a dedicated sales organization.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Chipmaker Advanced Micro Devices Inc. said Thursday after the markets closed that its first quarter loss narrowed from last year, helped by strong revenue growth in its graphics and visual solutions business. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly revenue. After trending higher over the past few sessions, stocks showed a lack of direction throughout the trading day on Thursday. The major averages spent the session bouncing back and forth across the unchanged line before ending the day mixed. While the major averages closed on opposite sides of the unchanged line, they all showed only modest moves. U.S. Secretary Of State John Kerry said Thursday that he and his counterparts from Russia, Ukraine and the European Union have reached an agreement on a preliminary plan for ending the ongoing crisis in Ukraine. Kerry was speaking at the end of the Ukraine contact group's first meeting, comprising the foreign ministers of Russia, Ukraine, the EU and the U.S., in the Swiss city of Geneva.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.